Thomas W. Flaig
About
Thomas W. Flaig is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology.
According to data from OpenAlex, Thomas W. Flaig has authored 209 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Pulmonary and Respiratory Medicine, 91 papers in Surgery and 73 papers in Oncology. Recurrent topics in Thomas W. Flaig's work include Bladder and Urothelial Cancer Treatments (83 papers), Prostate Cancer Treatment and Research (70 papers) and Urinary and Genital Oncology Studies (46 papers). Thomas W. Flaig is often cited by papers focused on Bladder and Urothelial Cancer Treatments (83 papers), Prostate Cancer Treatment and Research (70 papers) and Urinary and Genital Oncology Studies (46 papers). Thomas W. Flaig collaborates with scholars based in United States, Canada and France. Thomas W. Flaig's co-authors include Fred Saad, Karim Fizazi, Johann S. de Bono, Neal D. Shore, Howard I. Scher, Andrew J. Armstrong, Cora N. Sternberg, Paul N. Mainwaring, Bryan Selby and Ronald de Wit and has published in prestigious journals such as New England Journal of Medicine, Advanced Materials and Journal of Clinical Oncology.
In The Last Decade
Thomas W. Flaig
198 papers receiving 7.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Thomas W. Flaig United States | 38 | 5.2k | 2.3k | 2.1k | 1.7k | 1.6k | 209 | 7.9k | ||
| Glenn Liu United States | 46 | 4.9k 0.9× | 2.8k 1.2× | 2.5k 1.2× | 1.8k 1.0× | 411 0.3× | 175 | 8.5k | ||
| Paul N. Mainwaring Australia | 36 | 6.9k 1.3× | 2.7k 1.2× | 2.4k 1.1× | 2.4k 1.5× | 448 0.3× | 143 | 9.2k | ||
| Noah M. Hahn United States | 44 | 4.5k 0.9× | 4.4k 1.9× | 2.2k 1.1× | 1.6k 1.0× | 5.7k 3.5× | 261 | 11.4k | ||
| Daniel D. Karp United States | 43 | 3.8k 0.7× | 4.8k 2.1× | 2.9k 1.4× | 1.6k 1.0× | 1.0k 0.6× | 217 | 9.4k | ||
| Edward S. Kim United States | 52 | 5.3k 1.0× | 5.2k 2.2× | 2.9k 1.4× | 1.9k 1.1× | 691 0.4× | 216 | 9.8k | ||
| William L. Dahut United States | 56 | 4.3k 0.8× | 5.2k 2.2× | 3.2k 1.5× | 1.6k 1.0× | 669 0.4× | 291 | 10.4k | ||
| Vesa Kataja Finland | 49 | 2.1k 0.4× | 4.0k 1.7× | 2.5k 1.2× | 2.3k 1.4× | 1.6k 1.0× | 176 | 9.1k | ||
| Bernard Têtu Canada | 54 | 2.3k 0.4× | 2.7k 1.2× | 2.6k 1.3× | 1.5k 0.9× | 1.5k 0.9× | 196 | 8.4k | ||
| Wael Sakr United States | 56 | 5.2k 1.0× | 3.0k 1.3× | 3.1k 1.5× | 2.2k 1.3× | 2.9k 1.8× | 214 | 11.4k | ||
| Siqing Fu United States | 51 | 2.4k 0.5× | 4.1k 1.8× | 3.8k 1.8× | 2.4k 1.5× | 837 0.5× | 412 | 9.6k |
Countries citing papers authored by Thomas W. Flaig
Since
Specialization
Citations
This map shows the geographic impact of Thomas W. Flaig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas W. Flaig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas W. Flaig more than expected).
Fields of papers citing papers by Thomas W. Flaig
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Thomas W. Flaig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas W. Flaig. The network helps show where Thomas W. Flaig may publish in the future.
Co-authorship network of co-authors of Thomas W. Flaig
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas W. Flaig. A scholar is included among the top collaborators of Thomas W. Flaig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas W. Flaig. Thomas W. Flaig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lee, Jin Gyun, Alex C. Hughes, Lih‐Jen Su, et al.. (2025). Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers. Advanced Materials. 37(38). e2505231–e2505231.
2.
Friedlander, Terence W., Peter H. O’Donnell, Daniel P. Petrylak, et al.. (2025). 3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y. Annals of Oncology. 36. S1487–S1488.
3.
Robin, Tyler P., et al.. (2024). Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database. Urologic Oncology Seminars and Original Investigations. 42(12). 447.e17–447.e24.
4.
Plimack, Elizabeth R., Catherine M. Tangen, Melissa Plets, et al.. (2024). Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. European Urology. 86(4). 297–300.
5.
Kohli, Manish, Gregory Riedlinger, Eric A. Singer, et al.. (2024). Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations. Clinical Genitourinary Cancer. 23(1). 102293–102293.
6.
Sadeghi, Sarmad, Nataliya Mar, Denice Tsao‐Wei, et al.. (2024). Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 42(16_suppl). 4577–4577.
7.
Bourlon, María T., et al.. (2023). Racial differences in survival for early stage (T1) penile cancer: Analysis from the SEER database. Urologic Oncology Seminars and Original Investigations. 41(8). 359.e15–359.e23.
8.
Clark, Nathan P., Elizabeth R. Kessler, Elaine T. Lam, et al.. (2023). Use of Peripheral Intravenous Access in Patients Undergoing Chemotherapy for Testicular Cancer. JCO Oncology Practice. 20(3). 361–369.
9.
Kessler, Elizabeth R., Eryn Callihan, Junxiao Hu, et al.. (2023). A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma. Cancer Research Communications. 3(6). 1004–1012.
10.
Hoimes, Christopher, Thomas W. Flaig, Matthew I. Milowsky, et al.. (2023). A Plain Language Summary Exploring a New Treatment Combination for Untreated Locally Advanced or Metastatic Urothelial Cancer: Enfortumab Vedotin Plus Pembrolizumab. Future Oncology. 20(7). 351–360.
11.
Hoimes, Christopher, Thomas W. Flaig, Matthew I. Milowsky, et al.. (2022). Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. Journal of Clinical Oncology. 41(1). 22–31.
12.
Bourlon, María T., Elisabeth Meyer, Elizabeth R. Kessler, et al.. (2022). Patterns of Treatment and Outcomes in Older Men With Penile Cancer: A SEER Dataset Analysis. Frontiers in Oncology. 12. 926692–926692.
13.
Flaig, Thomas W., Catherine M. Tangen, Siamak Daneshmand, et al.. (2021). A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clinical Cancer Research. 27(9). 2435–2441.
14.
Petrylak, Daniel P., Raffaele Ratta, Rustem Gafanov, et al.. (2021). KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer. Future Oncology. 17(25). 3291–3299.
15.
Flaig, Thomas W., et al.. (2021). Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. 5(4). 167–179.
16.
Rosenberg, Jonathan E., Srikala S. Sridhar, Jingsong Zhang, et al.. (2020). EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. Journal of Clinical Oncology. 38(10). 1041–1049.
17.
Gulley, James L., Michael Borre, Nicholas J. Vogelzang, et al.. (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 37(13). 1051–1061.
18.
Solomon, James P., A. Karim Kader, J. Kellogg Parsons, et al.. (2016). Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?. Urology. 102. 7–16.
19.
Kavanagh, Brian D., Tracey E. Schefter, René González, et al.. (2010). Stereotactic Body Radiation Therapy for Melanoma and Renal Cell Carcinoma: Impact of Single Fraction Equivalent Dose on Local Control. International Journal of Radiation Oncology*Biology*Physics. 78(3). S190–S191.
20.
Saba, Nabil & Thomas W. Flaig. (2002). Bone Marrow Transplantation for Nonmalignant Diseases. Journal of Hematotherapy & Stem Cell Research. 11(2). 377–387.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Glenn Liu Breakdown of academic impact, for papers by Paul N. Mainwaring Breakdown of academic impact, for papers by Noah M. Hahn Breakdown of academic impact, for papers by Daniel D. Karp Breakdown of academic impact, for papers by Edward S. Kim Breakdown of academic impact, for papers by William L. Dahut Breakdown of academic impact, for papers by Vesa Kataja Breakdown of academic impact, for papers by Bernard Têtu Breakdown of academic impact, for papers by Wael Sakr Breakdown of academic impact, for papers by Siqing Fu